- |||||||||| febuxostat / Generic mfg., allopurinol / Generic mfg.
Review, Journal: Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial. (Pubmed Central) - Sep 25, 2023
Consequently, it is important for the product labeling information of both allopurinol and febuxostat to present and describe the current safety data to guide healthcare practitioners when prescribing these medications to patients. Pharmacovigilance and post-marketing pharmacoepidemiology data are essential in establishing the comprehensive safety profile.
- |||||||||| febuxostat / Generic mfg., allopurinol / Generic mfg.
Identifying and Addressing Suboptimal Urate Lowering Therapy in Gout Patients with Chronic Kidney Disease (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3895;
Many of these patients are not being treated to goal with suboptimal doses of urate-lowering therapy or no urate-lowering therapy at all. We speculate that this trend may be due to a number of reasons including gaps in knowledge by primary care regarding ULT in patients with a diagnosis of CKD and/or inaccurately in the "normal" range for serum uric acid in the EHR (abnormal is defined as 8 or above).
- |||||||||| prednisone / Generic mfg., allopurinol / Generic mfg.
Understanding Community Perspectives on Disease Management: A Social Media Analysis of Gout Care Strategies (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3324;
In comparing the top 5 most positive management topics, uric acid monitoring achieved the highest mean sentiment. Though the functional impact of sentiment differences is not easily appraised, these contrasts could suggest that gout community members tend to prefer uric acid monitoring over reactive management approaches such as prednisone.
- |||||||||| febuxostat / Generic mfg.
Human Cardiovascular Disease Model Provides Transcriptomic Evidence of Cardiovascular Risk Associated with Febuxostat (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3262;
Febuxostat significantly modulated more signaling pathways associated with cell stress and cardiovascular risk than allopurinol or topiroxostat, gout medications not associated with increased cardiovascular risk. Together, these data support the FDA warning for febuxostat and suggest that cardiovascular risk associated with gout medications stems from chemical structure of the medication, itself, rather than the target, xanthine oxidase.
- |||||||||| allopurinol / Generic mfg.
The Tophus Impact Questionnaire (TIQ-20): Responsiveness to Change During Urate-Lowering Therapy (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3238;
For people with tophaceous gout treated with allopurinol using a treat to target serum urate approach, improvements in TIQ-20 occur, as well as improvements in physical and imaging tophus measures. These findings demonstrate that the TIQ-20 is a responsive instrument of tophus burden.
- |||||||||| Krystexxa (pegloticase) / Amgen
Evaluation of Outcomes Following Discontinuation of Pegloticase Therapy (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3219;
An important minority of patients fail to receive any ULT after cessation of pegloticase. Additionally, many patients who were able to restart restarting pegloticase after a prolonged gap in therapy achieved had its expected resulting SU-lowering effect with therapy even after a gap in therapy, although the context for the interruption needs to be further explored.
- |||||||||| febuxostat / Generic mfg., allopurinol / Generic mfg.
Finding Lost-to-Care Gout Patients in a Large Community Rheumatology Network: Patient Re-engagement Initiative with Metrics (PRIME) (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3218;
Many of these patients were sub-optimally controlled (SU >6 mg/dL) at their last rheumatologist visit, suggesting that they may benefit from further rheumatology involvement. A quality improvement initiative is in development to better understand these patients' gout care needs and offer them an expedited visit with their rheumatology provider to re-engage them in care and potentially improve outcomes.
- |||||||||| Trial completion, Trial completion date: Allo HSCT Using RIC for Hematological Diseases (clinicaltrials.gov) - Sep 21, 2023
P2, N=156, Completed,
In order to improve testing rates, facilities should consider implementing order sets or pharmacy "hard stops" that require HLA-B*58:01 testing for high-risk groups. Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> May 2023
- |||||||||| Retrospective data, Review, Journal: Preventive effects of 13 different drugs on colorectal cancer: a network meta-analysis. (Pubmed Central) - Sep 21, 2023
The preventive effect of allopurinol on CRC was better than that of the other 13 drugs. These results can help doctors and patients understand the preventative effects of these drugs more intuitively and provide an evidence-based basis for the clinical application of these drugs.
- |||||||||| ebselen (SPI-1005) / Sound Pharma
Review, Journal: Ebselen: A Review on its Synthesis, Derivatives, Anticancer Efficacy and Utility in Combating SARS-COV-2. (Pubmed Central) - Sep 15, 2023
Allopurinol and ebselen administered orally can be used to suppress renal ototoxicity and nephrotoxicity...Ebselen may also inhibit the activation of endosomal NADPH oxidase of vascular endothelial cells, which is believed to be required for thrombotic complications in COVID-19. In this review, we have included various studies conducted on the anticancer effect of ebselen as well as its inhibition of SARS-CoV-2.
- |||||||||| simvastatin / Generic mfg., allopurinol / Generic mfg.
Hypereosinophilia of Undetermined Significance (Monitor 05) - Sep 14, 2023 - Abstract #ACAAI2023ACAAI_821;
Thorough evaluation for underlying reactive or neoplastic etiologies is necessary to establish the diagnosis, and patients should be monitored for symptomatic manifestations of hypereosinophilia. Retrospective analyses indicate that a small minority of patients progress to HES, though risk factors for progression are not well established.
- |||||||||| allopurinol / Generic mfg.
Atypical manifestations of DRESS syndrome without eosinophilia. Case report (Monitor 01) - Sep 14, 2023 - Abstract #ACAAI2023ACAAI_554;
We present the case of an atypic presentation without eosinophilia despite the "E" in DREES due to allopurinol consumption...10% of patients have no alterations in the eosinophil count and 30-50% have no lymphadenopathies making the diagnosis criteria more difficult. A proper clinical history and drug consumption may increase the accuracy in the diagnosis and offer a proper management to increase life expectancy.
- |||||||||| febuxostat / Generic mfg., allopurinol / Generic mfg.
Review, Journal: Mechanisms and rationale for uricase use in patients with gout. (Pubmed Central) - Sep 9, 2023
Uricases could become a leading choice in severe and difficult-to-treat gout as induction and/or debulking therapy (that is, for lowering of the urate pool) to be followed by chronic oral ULT. This Review summarizes the evidence regarding available uricases and those in the pipeline, their debulking effect and their outcomes related to gout and beyond.
- |||||||||| remdesivir / Generic mfg., methotrexate / Generic mfg., allopurinol / Generic mfg.
Toxic epidermal necrolysis in Slovenia (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_3825;
The reported rate for Steven Johnson syndrome has not been included in this report, but we believe it to be significantly lower, given that milder cases are often unrecognized. It is important to instill a culture of reporting among healthcare personnel, as it can greatly enhance the anticipation and identification of these rare, but potentially fatal, reactions.
- |||||||||| isotretinoin oral / Generic mfg., allopurinol / Generic mfg., ursodeoxycholic acid / Generic mfg.
Reactive perforating collagenosis secondary to primary biliary cirrhosis (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_3580;
Our patient had previously been known to Gastroenterology but was lost to follow up. Following her presentation, she was re-referred and was reviewed in their clinic for continued management of her PBC.
- |||||||||| allopurinol / Generic mfg.
A Case Of Gut Tophus Like Calcinosis Cutis (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_3534;
In conclusion, it should be kept in mind in clinical practice that tophi, which will occur as a result of delay in treatment in chronic cases, may lead to joint destruction. In our case, the importance of approaching the patient holistically and making a diagnosis with a holistic systematic examination and preventing complications was emphasized.
- |||||||||| allopurinol / Generic mfg.
Different pictures of allopurinol hypersensitivity syndrome (AHS) (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2404;
In our case, the importance of approaching the patient holistically and making a diagnosis with a holistic systematic examination and preventing complications was emphasized. The results of the analysis indicate a large contribution of allopurinol as a provocative factor in the occurrence of a severe drug reaction especially in patients in whom it was introduced because of asymptomatic hyperuricemia.
- |||||||||| warfarin / Generic mfg.
Breast necrosis induced by the use of coumadin (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2390;
The patient was also taking Allopurinol for gout disease and insulinotherapy for for diabetes...Management of coumadin-induced skin necrosis consists of discontinuation of coumadin replacing it with intravenous or subcutaneous heparin, and reversing the effects of the congener by administering vitamin K, fresh-frozen plasma, or both... The recognition of the diagnosis is an emergency because the necrosis evolves very quickly by involving the vital prognosis with 3-month mortality of 15%.
- |||||||||| Adcetris (brentuximab vedotin) / Seagen, Takeda
Hair repigmentation in a patient treating secondary Sezary syndrome. (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2374;
Pegylated interferon alfa2a may cause hair changes, as hair loss, hair thinning, and debatable, grey hair. Photopheresis has an immunomodulatory effect however its therapeutic mechanism is not well known.
- |||||||||| Adverse Cutaneous Reactions to psychotropic drugs (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2359;
Although they are rare and most often benign, and rarely require interruption of treatment, some effects are serious and threaten the functional and vital prognosis. We found in our study that anticonvulsants, particularly carbamazepine, were the psychotropic drugs most likely to cause adverse cutaneous reactions, essentially in the cases of high doses (> 400 mg for carbamazepine), rapid increase in doses, or association of several psychotropic drugs, especially lamotrigine with Valproate.
- |||||||||| ibuprofen / Generic mfg., allopurinol / Generic mfg.
Lichenoid Drug Eruptions: A Series of 17 cases (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2342;
Physicians should be aware of this type of reaction. Early detection of these cases has practical importance since the identification and elimination of the causative drug is essential for therapy success.
- |||||||||| carbamazepine / Generic mfg., allopurinol / Generic mfg.
Assessing liver damage in DRESS Syndrome: A clinical study of 61 Cases (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2341;
The study findings indicate that liver damage is a common complication of DRESS syndrome and can be life- threatening. Further studies with larger sample sizes are required to identify the main characteristics of liver dysfunction in DRESS syndrome, such as the clinical form, incriminating drug, associated visceral disorders, skin phenotype, and biological anomalies.
- |||||||||| imatinib / Generic mfg.
DRESS syndrome induced by Imatinib. (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2333;
For any patient presenting with rash and eosinophilia, any new drug should be discontinued, and low-dose steroids considered. A rechallenge with a lower dose is reasonable, failing which an alternative medication should be started.
- |||||||||| allopurinol / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: Effect of Allopurinol on Markers of Mineral and Bone Metabolism (clinicaltrials.gov) - Aug 29, 2023
P=N/A, N=50, Active, not recruiting,
Finally, B1, B2, B13 did not induce genotoxicity in a micronuclei murine model compared to CrO . Recruiting --> Active, not recruiting | Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Mar 2023 --> Dec 2023
|
